MITIGATING OCULAR TOXICITY
Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicit...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TALEKAR, Mala Kiran PAINTER, Jeffery Lanier |
| description | Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicity, and, if such signs are present, adjusting the dose of that component for a subsequent administration. Monitoring for signs of ocular toxicity may include performing an ophthalmic examination of the patient, including performing a visual assessment and corneal assessment of the patient. The ophthalmic examination may include selecting visual assessment options from predefined and selectable visual assessment options and include selection corneal assessment options from predefined and selectable corneal assessment options. An overall keratopathy visual acuity (KVA) grade may be determined based on the selected visual acuity assessment options and the selected corneal assessment options. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4476736A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4476736A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4476736A13</originalsourceid><addsrcrecordid>eNrjZJDy9QzxdHcM8fRzV_B3DvVxDFII8Y_wdPYMieRhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuASYm5mbmxmaOhsZEKAEACpggIw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MITIGATING OCULAR TOXICITY</title><source>esp@cenet</source><creator>TALEKAR, Mala Kiran ; PAINTER, Jeffery Lanier</creator><creatorcontrib>TALEKAR, Mala Kiran ; PAINTER, Jeffery Lanier</creatorcontrib><description>Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicity, and, if such signs are present, adjusting the dose of that component for a subsequent administration. Monitoring for signs of ocular toxicity may include performing an ophthalmic examination of the patient, including performing a visual assessment and corneal assessment of the patient. The ophthalmic examination may include selecting visual assessment options from predefined and selectable visual assessment options and include selection corneal assessment options from predefined and selectable corneal assessment options. An overall keratopathy visual acuity (KVA) grade may be determined based on the selected visual acuity assessment options and the selected corneal assessment options.</description><language>eng ; fre ; ger</language><subject>DIAGNOSIS ; HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA ; HUMAN NECESSITIES ; HYGIENE ; IDENTIFICATION ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS ; MEDICAL OR VETERINARY SCIENCE ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SURGERY</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241218&DB=EPODOC&CC=EP&NR=4476736A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241218&DB=EPODOC&CC=EP&NR=4476736A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TALEKAR, Mala Kiran</creatorcontrib><creatorcontrib>PAINTER, Jeffery Lanier</creatorcontrib><title>MITIGATING OCULAR TOXICITY</title><description>Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicity, and, if such signs are present, adjusting the dose of that component for a subsequent administration. Monitoring for signs of ocular toxicity may include performing an ophthalmic examination of the patient, including performing a visual assessment and corneal assessment of the patient. The ophthalmic examination may include selecting visual assessment options from predefined and selectable visual assessment options and include selection corneal assessment options from predefined and selectable corneal assessment options. An overall keratopathy visual acuity (KVA) grade may be determined based on the selected visual acuity assessment options and the selected corneal assessment options.</description><subject>DIAGNOSIS</subject><subject>HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>IDENTIFICATION</subject><subject>INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SURGERY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJDy9QzxdHcM8fRzV_B3DvVxDFII8Y_wdPYMieRhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuASYm5mbmxmaOhsZEKAEACpggIw</recordid><startdate>20241218</startdate><enddate>20241218</enddate><creator>TALEKAR, Mala Kiran</creator><creator>PAINTER, Jeffery Lanier</creator><scope>EVB</scope></search><sort><creationdate>20241218</creationdate><title>MITIGATING OCULAR TOXICITY</title><author>TALEKAR, Mala Kiran ; PAINTER, Jeffery Lanier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4476736A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>DIAGNOSIS</topic><topic>HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>IDENTIFICATION</topic><topic>INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SURGERY</topic><toplevel>online_resources</toplevel><creatorcontrib>TALEKAR, Mala Kiran</creatorcontrib><creatorcontrib>PAINTER, Jeffery Lanier</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TALEKAR, Mala Kiran</au><au>PAINTER, Jeffery Lanier</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MITIGATING OCULAR TOXICITY</title><date>2024-12-18</date><risdate>2024</risdate><abstract>Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicity, and, if such signs are present, adjusting the dose of that component for a subsequent administration. Monitoring for signs of ocular toxicity may include performing an ophthalmic examination of the patient, including performing a visual assessment and corneal assessment of the patient. The ophthalmic examination may include selecting visual assessment options from predefined and selectable visual assessment options and include selection corneal assessment options from predefined and selectable corneal assessment options. An overall keratopathy visual acuity (KVA) grade may be determined based on the selected visual acuity assessment options and the selected corneal assessment options.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP4476736A1 |
| source | esp@cenet |
| subjects | DIAGNOSIS HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA HUMAN NECESSITIES HYGIENE IDENTIFICATION INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SURGERY |
| title | MITIGATING OCULAR TOXICITY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A16%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TALEKAR,%20Mala%20Kiran&rft.date=2024-12-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4476736A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |